Inhaled corticosteroids are the cornerstone of the modern therapy for
asthma. In recent years, inhaled corticosteroids have been used in hig
her doses than previously. This has caused concern about possible oste
oporotic side-effects. We studied bone mineral densities (BMDs) in 19
non-smoking women (mean age 53 years, range 40-63) with newly diagnose
d bronchial asthma and 19 voluntary healthy nonsmoking women (mean age
53 years, range 43-67). In both groups, 13 subjects were postmenopaus
al. Patients started beclomethasone dipropionate from the spacer 500 m
u g twice daily as the sole corticosteroid therapy. BMDs were mea sure
d with dual-energy x-ray absorptiometry (DEXA) at the lumbar spine (L2
-4) and at the left proximal femur (the neck, Ward's triangle and the
trochanteric region). The measurements were made at baseline and 6 and
12 months thereafter. No significant changes were observed in the mea
sured BMDs in either study group. The results show that inhaled beclom
ethasone dipropionate therapy 1000 mu g/day for one year does not affe
ct BMD. Further studies are needed to assess the effects of inhaled 'c
orticosteroid on BMD during a longer treatment period.